Theravance Biopharma, Inc. (TBPH)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGM
16.78 USD
+0.06
(0.359%)
⇧
(April 21, 2026, 1:41 p.m.
EDT)
Short-term: ★★★☆☆ | Long-term: ★★★☆☆ | Dividends: ★☆☆☆☆ |
Hot Take | April 18, 2026, 10:41 p.m. EDT
TBPH presents a classic 'between-year earnings' setup: risky fundamental discontinuity (Nasdaq bid, bankruptcy risk) masking a statistically neutral short-term fair value (-1% forecast). The chart is merely a technical bounce, not a momentum shift, supported by invariant analyst consensus trading the exact current price. The asymmetric aggression in long-dated calls ($20/$25 options) is the only genuine source of potential upside, but for a standard investor, the limited downside protection and lack of fundamental catalysts justify a watch-for-those-buy signal rather than a conviction entry. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.175545 |
| AutoARIMA | 0.175582 |
| MSTL | 0.177908 |
| AutoTheta | 0.191701 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 61.61 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.117 |
| Excess Kurtosis | -1.50 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 14.392 |
| Revenue per Share | 2.136 |
| Market Cap | 864,051,328 |
| Trailing P/E | 8.15 |
| Forward P/E | 12.38 |
| Beta | 0.17 |
| Profit Margins | 98.54% |
| Website | https://www.theravance.com |
As of April 18, 2026, 10:41 p.m. EDT: Options data reveals a pronounced divergence in sentiment based on expiration. For the near term (April 17, May 15), put writing/holding (straddles/strangles implied by high atm_iv on puts) dominates, suggesting a defensive 'buy weakness' or hedging stance. However, medium-term expiry data (June 18 and Dec 18) shows aggressive positioning in out-of-the-money calls, with significant open interest at $20 and $25 strikes. This indicates that while short-term volatility is feared, long-term speculators are positioning for a multi-month leg up past $20.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.79591835 |
| Address1 | 901 Gateway Boulevard |
| All Time High | 43.44 |
| All Time Low | 6.1 |
| Ask | 21.42 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 2.0 - Buy |
| Average Daily Volume10 Day | 392,440 |
| Average Daily Volume3 Month | 633,850 |
| Average Volume | 633,850 |
| Average Volume10Days | 392,440 |
| Beta | 0.165 |
| Bid | 12.14 |
| Bid Size | 2 |
| Board Risk | 2 |
| Book Value | 5.81 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 3 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 16.78 |
| Current Ratio | 10.925 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 16.95 |
| Day Low | 16.46 |
| Debt To Equity | 14.392 |
| Display Name | Theravance Biopharma |
| Earnings Call Timestamp End | 1,762,812,000 |
| Earnings Call Timestamp Start | 1,762,812,000 |
| Earnings Timestamp | 1,773,923,400 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | -1,976,000 |
| Ebitda Margins | -0.01839 |
| Enterprise To Ebitda | -297.727 |
| Enterprise To Revenue | 5.474 |
| Enterprise Value | 588,307,712 |
| Eps Current Year | 4.4 |
| Eps Forward | 1.355 |
| Eps Trailing Twelve Months | 2.06 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 16.4631 |
| Fifty Day Average Change | 0.31690025 |
| Fifty Day Average Change Percent | 0.019249123 |
| Fifty Two Week Change Percent | 79.591835 |
| Fifty Two Week High | 21.03 |
| Fifty Two Week High Change | -4.25 |
| Fifty Two Week High Change Percent | -0.20209225 |
| Fifty Two Week Low | 8.33 |
| Fifty Two Week Low Change | 8.450001 |
| Fifty Two Week Low Change Percent | 1.0144058 |
| Fifty Two Week Range | 8.33 - 21.03 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,400,247,000,000 |
| Float Shares | 24,128,039 |
| Forward Eps | 1.355 |
| Forward P E | 12.383764 |
| Free Cashflow | -4,116,375 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 90 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.65185 |
| Gross Profits | 70,050,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03946 |
| Held Percent Institutions | 0.98165 |
| Implied Shares Outstanding | 51,492,924 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California. |
| Long Name | Theravance Biopharma, Inc. |
| Market | us_market |
| Market Cap | 864,051,328 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_240999442 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 105,895,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 861,476,618 |
| Number Of Analyst Opinions | 5 |
| Open | 16.64 |
| Operating Cashflow | 238,540,992 |
| Operating Margins | 0.43605 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Phone | 650 808 6000 |
| Previous Close | 16.72 |
| Price Eps Current Year | 3.8136365 |
| Price Hint | 2 |
| Price To Book | 2.888124 |
| Price To Sales Trailing12 Months | 8.04038 |
| Profit Margins | 0.9854 |
| Quick Ratio | 10.728 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.0 |
| Region | US |
| Regular Market Change | 0.060001373 |
| Regular Market Change Percent | 0.3588599 |
| Regular Market Day High | 16.95 |
| Regular Market Day Low | 16.46 |
| Regular Market Day Range | 16.46 - 16.95 |
| Regular Market Open | 16.64 |
| Regular Market Previous Close | 16.72 |
| Regular Market Price | 16.78 |
| Regular Market Time | 1,776,793,277 |
| Regular Market Volume | 223,494 |
| Return On Assets | -0.0053600003 |
| Return On Equity | 0.44845 |
| Revenue Growth | 1.447 |
| Revenue Per Share | 2.136 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 51,492,924 |
| Shares Percent Shares Out | 0.1022 |
| Shares Short | 5,262,895 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 4,760,447 |
| Short Name | Theravance Biopharma, Inc. |
| Short Percent Of Float | 0.1626 |
| Short Ratio | 5.53 |
| Source Interval | 15 |
| State | CA |
| Symbol | TBPH |
| Target High Price | 21.0 |
| Target Low Price | 15.0 |
| Target Mean Price | 17.2 |
| Target Median Price | 17.0 |
| Total Cash | 315,356,992 |
| Total Cash Per Share | 6.124 |
| Total Debt | 42,703,000 |
| Total Revenue | 107,464,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 2.06 |
| Trailing P E | 8.145632 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 15.710225 |
| Two Hundred Day Average Change | 1.0697756 |
| Two Hundred Day Average Change Percent | 0.068094224 |
| Type Disp | Equity |
| Volume | 223,494 |
| Website | https://www.theravance.com |
| Zip | 94,080 |